Abel R M, van Gelder H M, Pores I H, Liguori J, Gielchinsky I, Parsonnet V
Arch Surg. 1983 Jun;118(6):727-31. doi: 10.1001/archsurg.1983.01390060045010.
One hundred consecutive patients requiring propranolol hydrochloride before undergoing isolated aortocoronary bypass procedures were examined. In half the patients, propranolol therapy was discontinued, whereas the other half continued to receive intraoperative and postoperative propranolol regardless of clinical events. Although there were no preoperative differences in the apparent degree of coronary arterial disease or left ventricular function in the two groups, postoperative supraventricular arrhythmias were less frequent in the propranolol-treated group, most noticeably in those receiving less than 320 mg preoperatively. In patients who had received large preoperative doses (greater than or equal to 320 mg/day), there were no significant differences in postoperative supraventricular tachycardias. Continued propranolol therapy following isolated coronary bypass surgery appears to be a safe and efficacious method of decreasing the incidence of postoperative supraventricular tachycardias.
对100例在接受单纯主动脉冠状动脉搭桥手术前需要使用盐酸普萘洛尔的连续患者进行了检查。在一半患者中，普萘洛尔治疗中断，而另一半患者无论临床情况如何，继续接受术中和术后的普萘洛尔治疗。尽管两组患者术前冠状动脉疾病的明显程度或左心室功能没有差异，但普萘洛尔治疗组术后室上性心律失常的发生率较低，最明显的是术前接受剂量小于320mg的患者。在术前接受大剂量（大于或等于320mg/天）的患者中，术后室上性心动过速没有显著差异。冠状动脉搭桥手术后继续使用普萘洛尔治疗似乎是一种安全有效的降低术后室上性心动过速发生率的方法。
